Tech Company Inital Public Offerings
CinCor Pharma IPO
CinCor Pharma, based in Cincinnati, went public on 1/7/2022.
Transaction Overview
Company Name
Announced On
1/7/2022
Transaction Type
IPO
Amount
$193,600,000
Proceeds Purpose
CinCor Pharma will use the proceeds to fund the clinical development of CIN-107, as well as for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5375 Medpace Way
Cincinnati, OH 45227
USA
Cincinnati, OH 45227
USA
Phone
Undisclosed
Website
Email Address
Overview
CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor's focus is on cardiovascular, metabolic and kidney diseases. CinCor's lead program is CIN-107, a novel aldosterone synthase inhibitor.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jon Isaacsohn
Chief Operating Officer
Catherine Pearce
VP - Bus. Development
Justin Thompson
VP - Operations
Brendan Doran
Browse more venture capital transactions:
Prev: 1/7/2022: Finexio venture capital transaction
Next: 1/7/2022: Amberstone Biosciences venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs